

Q3 2020 - Presentation



November 05, 2020

Disclaimer

This presentation includes forward-looking information and statements that are subject to risks and uncertainties that could cause actual results to differ. Such forward-looking information and statements are based on current expectations, estimates and projections about global economic conditions, the economic conditions of the regions and industries that are major markets for IDEX Biometrics ASA (IDEX) and its subsidiaries. These expectations, estimates and projections are generally identifiable by statements containing words such as "expects", "believes", "estimates" or similar expressions. Important factors that could cause actual results to differ materially from those expectations include, among others, economic and market conditions in the geographic areas and industries that are or will be major markets for the IDEX businesses, market acceptance of new products and services, changes in governmental regulations, interest rates, fluctuations in currency exchange rates and such other factors as may be discussed from time to time. Although IDEX believes that its expectations and the information in this presentation were based upon reasonable assumptions at the time when they were made, it can give no assurance that those expectations will be achieved or that the actual results will be as set out in this presentation. IDEX Biometrics ASA nor any other company within the IDEX Group is making any representation or warranty, expressed or implied, as to the accuracy, reliability or completeness of the information in the presentation, and neither IDEX Biometrics ASA, any other company within the IDEX Group nor any of their directors, officers or employees will have any liability to you or any other persons resulting from your use of the information in this presentation. IDEX Biometrics ASA undertakes no obligation to publicly update or revise any forward-looking information or statements in this presentation.

Recent Highlights

- Commercial momentum accelerating with issuers and banks for biometric payment cards
 - Covid-19 rapidly accelerating contactless payments
 - Multiple new orders from new integrators and geographies suggest broad demand
- Payment card market
 - Production orders from a Tier 1 global payment card manufacturer
 - Large volume order from Zwipe
 - Volume orders from Hengbao, one of the largest smart card companies in China
 - Design wins and orders from new global card manufacturers
- Other markets
 - Production shipments ongoing to the large IT and financial services customer
 - Volume production orders for both current and next generation products from customer in Korea
- Banking industry executives added to the board of directors and strategic advisory committee
- Filed registration statement with US SEC to dual list on the Nasdaq

Investment Highlights

Massive Addressable Market	• 22B payment cards in circulation and 5B new cards issued every year ⁽¹⁾ • Contactless cards have accelerated significantly; >75% of EU transaction now contactless, >50% of Americans now using contactless payment cards • USD 2B+ biometric payment cards by 2024; 200% plus CAGR for biometric payment card shipments
Large-Scale Certification	• First certified and commercially ready cards delivered in Q1 2020 • Certification with China UnionPay and one other global payment network (EMVCo® certified) • Both platforms represent 70% of all global branded payment cards
Sales and Pipeline Momentum	• Europe: Orders from several customers received • Asia: Certifications achieved, and production orders received • Other: USD 6M contract with financial markets data provider, first production orders delivered in 2020
Defensible IP / Technology	• TrustedBio: full system solution enables highest performing and lowest cost cards in the industry • 200 plus patents granted or pending patents • Full EMVCo® certified on card level as well as component level
Highly Experienced Management	• Accomplished executive team with experience bringing new technologies to market • Management and board with significant experience managing public companies

Consumer Benefits



Security

- Eliminates lost/stolen, friendly fraud
- Identity protection
- Fully encrypted, resistant to logical attacks
- Peace of mind



Convenience

- Fast, simple, secure transactions
- Hygienic, “touch-free” payments; no pins, battery anxiety or connectivity issues




Prestige

- High “cool factor”, like metal cards
- Differentiated, high-technology payment cards consumers will pay for




Market activation milestones



Lowering Manufacturing Complexity and Card Cost

TrustedBio™ yields cost, performance, and reduced manufacturing complexity


\$40+



FIRST GENERATION CARD

- Battery/supercapacitor
- Complex and expensive flexible PCB (MCU, companion chip, basic PMU)
- Complex embedding (12+ connections to sensor)


~\$15 - \$20



CURRENT GENERATION CARDS

- No battery or supercapacitor
- Simplified flexible PCB with discrete components (MCU, PMU)
- Improvement of manufacturing/ACF Compatible

~\$5



IDEX TrustedBio™ CARDS

- Fully Integrated, Improved Performance
- Passive inlay, copper-wire compliant
- Stabilized manufacturing process (4 or 8 pads)


Strong Operating Leverage in Financial Model

Fabless semiconductor model:

- Complete solution including ASIC, Sensor, and Biometric Software
- 50%+ gross margins and stable opex at scale
- 30% operating margins at scale

Stable operating expense model

Cash Operating Expenses¹ in USD (millions)



¹Cash Operating Expenses is operating expense excluding stock compensation and development inventory and intangibles reserve related to a discontinued product in Q4 of 2019

Financial Summary

- Revenue in the third quarter was USD 248 thousand compared to USD 149 thousand in the third quarter of 2019
- Product revenue was USD 246 thousand in the third quarter of 2020 compared to USD 53 thousand in the third quarter of 2019
- Product gross margin was 81% compared to 60% in the third quarter of 2019
- Operating expenses were USD 6.6 million compared to USD 7.0 million in the third quarter of 2019
 - Excluding one-time costs¹, operating costs were USD 6.0 million
- Operating costs in the third quarter included USD 1.1 million of stock-based compensation
- Balance Sheet
 - The company ended the third quarter with USD 5.7 million in cash and no financial debt

¹ Excluding one-time costs associated with a U.S. stock listing filing

Summary and Outlook

- Significant commercial progress – new geographies and integrators
- Multiple card manufacturers certified on multiple payment networks
- First production orders for our next generation TrustedBio™ product
- Accelerating sales; volume shipments have begun
- Rapid acceleration in volume deployments expected in 2021 through several to-be-announced commercial launches by banks in several geographies
- Addressable market is expected to steadily grow to 3 billion units

Thank You



IDEX